Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Cuts Q2 Loss on Lower Spending

NEW YORK (GenomeWeb News) – Med BioGene late Friday reported that it cut its second-quarter net loss 17 percent due to a decreased R&D spending.
 
The Vancouver, British Columbia-based molecular diagnostics firm reported no revenues for the quarter.
 
Its net loss dropped to $616,733, or $.02 per share, compared to a loss of $741,421, or $.03 per share, for the second quarter of 2007. “The decrease was a result of reduced stock-based compensation expenses and reduced laboratory supply expenses partially offset by increased business development costs as MBI continues to develop and execute upon its commercialization strategy,” the firm said in a statement.
 
MBI’s R&D expenses fell to $261,101 from $399,867 year over year, while its general and administrative costs inched up to $336,207 from $326,020 in the second quarter of 2007.
 
The firm is gearing up for the launch of LungExpress Dx, a gene expression-based prognostic test for lung cancer, which it hopes to market in 2009.
 
MBI finished the quarter with $397,079 in cash and cash equivalents.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.